Physician profile

John Thomas Raabe

General Practice (Dentist) · Denver, CO

NPI 1770606717

$1,973.82

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Gift$1,743.17
Food and Beverage$141.75
Education$25.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ultradent Products INC $1,743.17 2023 Opalescence
Nobel Biocare USA $67.25 2019-2023 Nobelactive
Biolase, INC. $48.26 2023 Waterlase Iplus
Zimvie INC. $39.18 2023
Hu-Friedy Mfg. Co., LLC $25.00 2023
Dentsply Ih INC. $21.84 2019
Solventum Corporation $16.61 2024 Clinpro 5000, 3m Relyx, 3m Espe Filtek Supreme Ultra Universal Restorative
Dmg America LLC $12.51 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John Thomas Raabe

$1,973.82

in general payments reported 2019-2025

Years
2019-2024
Top company
Ultradent Products INC

https://glasscript.com/doctor/170787/john-thomas-raabe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.